US M&A and equity raisings
3,392 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
Deals dated after 30 September 2026 are still being collected.
64 deals · US$76bndisclosed · Pharma · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Jun 2025 | Felix Pharmaceuticals Pvt | – | Advent International | Stake | Announced | – | Animal Health+2 | A&L Goodbody LLPLincoln International (sell-side)Guggenheim Securities (buy-side) |
| Jul 2025 | Altanine | – | Polomar Health Services | Merger | Pending | – | Healthcare+1 | |
| Sep 2025 | Zentiva | Advent International | GTCR | Acquisition | Announced | – | Pharma+1 | Goldman Sachs (sell-side)PJT Partners (sell-side)Freshfields (sell-side)Barclays (buy-side)BNP Paribas (buy-side)Morgan Stanley (buy-side)Kirkland & Ellis (buy-side) |
| Dec 2025 | MindWave Innovations | – | Apimeds Pharmaceuticals US | Merger | Completed | – | Biotech+1 | Duane Morris (sell-side)Nelson Mullins Riley & Scarborough (buy-side) |
| Dec 2025 | Amicus Therapeutics | – | BioMarin | Acquisition | Announced | 4,800.0 | Biotech+2 | Centerview Partners (sell-side)Goldman Sachs (sell-side)Kirkland & Ellis (sell-side)Morgan Stanley (buy-side)Jones Day (buy-side) |
| Dec 2025 | Dynavax Technologies | – | Sanofi | Acquisition | Announced | 2,200.0 | Biotech+1 | Centerview Partners (sell-side)Goldman Sachs (sell-side)Cooley (sell-side)Weil, Gotshal & Manges (buy-side) |
| 2026 | Egetis | – | ANI Pharmaceuticals | Acquisition | Announced | 560.0 | Pharma+1 | Centerview Partners (sell-side) |
| Jan 2026 | Wonderbelly | – | Procter & Gamble | Acquisition | Completed | – | Consumer Health+1 | Perella Weinberg Partners (sell-side) |
| Jan 2026 | Lantheus SPECT business | Lantheus | SHINE Technologies | Asset sale | Announced | – | Pharma+2 | Solomon Partners (sell-side) |
| Jan 2026 | Nivagen Pharmaceuticals | – | PAI Pharma | Acquisition | Announced | – | Pharmaceutical Manufacturing+1 | Bourne Partners (buy-side)Kirkland & Ellis (buy-side)KPMG (buy-side) |
| Jan 2026 | PTC Therapeutics' remaining royalty on Roche's Evrysdi | PTC Therapeutics | Royalty Pharma | Asset sale | Announced | 240.0 | Specialty finance and leasing+2 | Goodwin (buy-side) |
| Jan 2026 | Ventyx Biosciences | – | Eli Lilly and Company | Acquisition | Announced | 1,200.0 | Biotech+2 | Jefferies (sell-side)Moelis & Company (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)BofA Securities (buy-side)Ropes & Gray (buy-side) |
| Jan 2026 | Radius Health | Patient Square Capital | B-FLEXION Life Sciences | Acquisition | Announced | – | Pharma | Kirkland & Ellis (sell-side)Centerview Partners (sell-side) |
| Jan 2026 | TerSera Infusion Specialty Therapies Business Unit (IST) | TerSera Therapeutics | ESTEVE | Asset sale | Pending | – | Pharma | Kirkland & Ellis (sell-side)Leerink Partners (sell-side)Perella Weinberg Partners (buy-side)Arnold & Porter (buy-side) |
| Feb 2026 | Orna Therapeutics | – | Eli Lilly and Company | Acquisition | Announced | 2,400.0 | Biotech+1 | Lazard (sell-side)Goodwin (sell-side)Paul, Weiss (buy-side) |
| Feb 2026 | Avadel Pharmaceuticals | – | Alkermes | Scheme | Completed | – | Pharma+1 | Goldman Sachs (sell-side)Morgan Stanley (sell-side)J.P. Morgan (buy-side) |
| Feb 2026 | AiCuris Anti-infective Cures AG | – | Veloxis Pharmaceuticals | Acquisition | Announced | 913.0 | Pharma+1 | Gibson Dunn (sell-side)Freshfields (buy-side) |
| Mar 2026 | Transcend Therapeutics | – | Otsuka | Acquisition | Announced | 700.0 | Biotech+2 | Kirkland & Ellis (sell-side)Goodwin (sell-side)Centerview Partners (sell-side)Skadden, Arps, Slate, Meagher & Flom (buy-side) |
| Mar 2026 | Paratek Pharmaceuticals | – | – | Merger | Completed | – | Pharma | Skadden, Arps, Slate, Meagher & Flom |
| Mar 2026 | Manufacturing facility in Phoenix, AZ | Bristol Myers Squibb | Rovi | Asset sale | Completed | – | Pharmaceutical Manufacturing+1 | William Blair |
| Mar 2026 | Corstasis Therapeutics | – | Esperion Therapeutics | Acquisition | Completed | 75.0 | Pharma+1 | PJT Partners (sell-side)Arnold & Porter (sell-side)Jefferies (buy-side)Gibson Dunn (buy-side) |
| Mar 2026 | Day One Biopharmaceuticals | – | Servier | Acquisition | Pending | 2,500.0 | Biotech+2 | Centerview Partners (sell-side)Fenwick & West (sell-side)Goldman Sachs (buy-side)Baker McKenzie (buy-side)Innisfree M&A (buy-side) |
| Mar 2026 | AZSTARYS business | Corium Therapeutics Holdings | Collegium Pharmaceutical | Asset sale | Pending | 650.0 | Pharma | Centerview Partners (sell-side)Sullivan & Cromwell (sell-side)Leerink Partners (buy-side)Goodwin (buy-side) |
| Mar 2026 | AnaptysBio outstanding common stock | – | AnaptysBio | Buy-back | Announced | 100.0 | Biotech+1 | Piper Sandler (buy-side) |
| Mar 2026 | Kezar Life Sciences | – | Aurinia Pharmaceuticals | Acquisition | Announced | 51.5 | Biotech+1 | TD Securities (sell-side)Cooley (sell-side) |
| Mar 2026 | Apellis Pharmaceuticals | – | Biogen | Acquisition | Announced | 5,600.0 | Biotech+2 | Lazard (buy-side)Evercore (sell-side)Wachtell, Lipton, Rosen & Katz (sell-side)WilmerHale (sell-side)Cravath, Swaine & Moore (buy-side) |
| Mar 2026 | Centessa Pharmaceuticals | – | Eli Lilly and Company | Scheme | Pending | 6,300.0 | Biotech+1 | Centerview Partners (sell-side)Jefferies (sell-side)Goodwin (sell-side)Morgan Stanley (buy-side)Kirkland & Ellis (buy-side) |
| Apr 2026 | Cumberland U.S. branded businesses | Cumberland Pharmaceuticals | Apotex | Asset sale | Announced | – | Pharma | Kirkland & Ellis (buy-side) |
| Apr 2026 | Modeyso commercial sales royalties | Former Oncoceutics Inc. securityholders | HealthCare Royalty | Asset sale | Announced | – | Specialty finance and leasing+3 | Latham & Watkins (sell-side) |
| Apr 2026 | Exclusive global rights to TAK-063 (balipodect) | Takeda Pharmaceutical Co. | Axsome Therapeutics | Asset sale | Completed | – | Pharma+1 | Sidley Austin (buy-side) |
| Apr 2026 | Soleno Therapeutics | – | Neurocrine Biosciences | Acquisition | Completed | 2,900.0 | Biotech+2 | Centerview Partners (sell-side)Guggenheim Securities (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)Goodwin (sell-side)Goldman Sachs (buy-side)Cooley (buy-side) |
| Apr 2026 | Assertio non-Rolvedon assets (Indocin, Sympazan, Sprix, Cambia, Zipsor, Otrexup) | Assertio Holdings | Cosette Pharmaceuticals | Asset sale | Completed | 35.0 | Pharma | Moelis & Company (sell-side)Gibson Dunn (sell-side) |
| Apr 2026 | Worldwide rights to Kenalog | Bristol-Myers Squibb | Subsidiary of Piramal Pharma | Asset sale | Announced | 35.0 | Pharma | Goodwin (buy-side) |
| Apr 2026 | Assertio Holdings | – | Zydus Worldwide DMCC | Acquisition | Announced | 166.4 | Pharma | Moelis & Company (sell-side)Gibson Dunn (sell-side)Longacre Square Partners (sell-side)Paul, Weiss (buy-side) |
| Apr 2026 | US sales and distribution rights for seven Assertio branded products | Assertio Holdings | Cosette Pharmaceuticals | Asset sale | Announced | – | Pharma | Gibson Dunn (sell-side) |
| Apr 2026 | Neurona Therapeutics | – | UCB | Acquisition | Announced | 650.0 | Biotech+2 | Centerview Partners (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)BofA Securities (buy-side)Covington & Burling (buy-side) |
| Apr 2026 | Kashiv BioSciences | – | Amneal Pharmaceuticals | Acquisition | Completed | 375.0 | Biotech+2 | J.P. Morgan (sell-side)Holland & Knight (sell-side)Goldman Sachs (buy-side)Richards, Layton & Finger (buy-side)Simpson Thacher & Bartlett (buy-side)Boston Consulting Group (buy-side) |
| Apr 2026 | Cumberland FDA-approved commercial products and related assets | Cumberland Pharmaceuticals | Nuvo Pharmaceuticals (Ireland) DAC | Asset sale | Pending | 100.0 | Pharma | VelocityHealth Securities (sell-side)Baker Donelson (sell-side)Kirkland & Ellis (buy-side) |
| Apr 2026 | Organon & Co. | – | Sun Pharmaceutical Industries | Acquisition | Announced | 11,750.0 | Pharma | Morgan Stanley (sell-side)Goldman Sachs (sell-side)Sullivan & Cromwell (sell-side)Cyril Amarchand Mangaldas (sell-side)J.P. Morgan (buy-side)Jefferies (buy-side)White & Case (buy-side)AZB & Partners (buy-side) |
| Apr 2026 | KalVista Pharmaceuticals | – | Chiesi Group | Acquisition | Completed | 1,900.0 | Pharma+2 | Centerview Partners (sell-side)Kirkland & Ellis (sell-side)Fenwick & West (sell-side)Jefferies (sell-side)Lazard (buy-side)Ropes & Gray (buy-side) |
| Apr 2026 | Shionogi-Apnimed Sleep Science | Apnimed | Shionogi & Co. | Acquisition | Announced | 100.0 | Pharma+1 | Goodwin (sell-side) |
| Apr 2026 | Emalex Biosciences | – | Teva Pharmaceuticals | Acquisition | Announced | 700.0 | Pharma+1 | Centerview Partners (sell-side)Bradley Arant Boult Cummings (sell-side)Evercore (buy-side)Faegre Drinker Biddle & Reath (buy-side) |
| May 2026 | Esperion Therapeutics | – | ARCHIMED | Acquisition | Pending | 1,100.0 | Pharma+1 | Latham & WatkinsCenterview Partners (sell-side)Goodwin (sell-side)Moelis & Company (buy-side)Sidley Austin (buy-side) |
| May 2026 | Catalyst Pharmaceuticals | – | Angelini Pharma S.p.A. | Acquisition | Pending | 4,100.0 | Pharma+1 | J.P. Morgan (sell-side)Kirkland & Ellis (sell-side)Akerman (sell-side)Centerview Partners (buy-side)BNP Paribas (buy-side)Morgan Stanley (buy-side)Hogan Lovells Cadwalader (buy-side)Gatti Pavesi Bianchi Ludovici (buy-side) |
| May 2026 | Orphai Therapeutics | – | Quince Therapeutics | Acquisition | Completed | – | Biotech+2 | Cooley (sell-side)LifeSci Capital (buy-side)Dorsey & Whitney (buy-side)Oppenheimer & Co. (buy-side)Gibson Dunn (buy-side) |
| May 2026 | Mentari Therapeutics | – | InMed Pharmaceuticals | Acquisition | Announced | – | Biotech+1 | Wedbush Securities (sell-side)Gibson Dunn (sell-side)Lucid Capital Markets (buy-side)Norton Rose Fulbright (buy-side) |
| May 2026 | Altruix | WindRose Health Investors | Frazier Healthcare Partners | Acquisition | Completed | – | Behavioral Health+1 | Houlihan Lokey (sell-side)Cantor Fitzgerald (sell-side)Latham & Watkins (sell-side)Goodwin (buy-side) |
| Jun 2026 | US generic and specialty pharmaceutical product portfolio of Nordic Pharma | Nordic Pharma | J. Molner | Asset sale | Completed | – | Pharma | Raymond James |
| Jun 2026 | Azora Therapeutics | – | Adial Pharmaceuticals | Asset sale | Completed | – | Biotech+2 | Lucid Capital Markets (sell-side)Honigman (sell-side)Oppenheimer & Co. (buy-side)Blank Rome (buy-side) |
| Jun 2026 | Theravance Biopharma | – | Zymeworks | Acquisition | Pending | 929.0 | Pharma+1 | Lazard (sell-side)Evercore (sell-side)Skadden, Arps, Slate, Meagher & Flom (sell-side)Arthur Cox (sell-side)Kirkland & Ellis (buy-side)Matheson (buy-side)MTS Health Partners (buy-side) |
Deals come from SEC filings (merger proxies, tender offers, 8-K announcements and IPO prospectuses), the deal pages and transaction lists of law firms and banks, companies' press releases and the press. How the data is built